These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 29484186)
61. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Rudin A; Riise GC; Holmgren J Infect Immun; 1999 Jun; 67(6):2884-90. PubMed ID: 10338495 [TBL] [Abstract][Full Text] [Related]
62. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Schenk DB; Koller M; Ness DK; Griffith SG; Grundman M; Zago W; Soto J; Atiee G; Ostrowitzki S; Kinney GG Mov Disord; 2017 Feb; 32(2):211-218. PubMed ID: 27886407 [TBL] [Abstract][Full Text] [Related]
63. The activation of the TLR2/p38 pathway by sodium butyrate in bovine mammary epithelial cells is involved in the reduction of Staphylococcus aureus internalization. Alva-Murillo N; Medina-Estrada I; Báez-Magaña M; Ochoa-Zarzosa A; López-Meza JE Mol Immunol; 2015 Dec; 68(2 Pt B):445-55. PubMed ID: 26471700 [TBL] [Abstract][Full Text] [Related]
64. Staphylococcus aureus Biofilms Induce Macrophage Dysfunction Through Leukocidin AB and Alpha-Toxin. Scherr TD; Hanke ML; Huang O; James DB; Horswill AR; Bayles KW; Fey PD; Torres VJ; Kielian T mBio; 2015 Aug; 6(4):. PubMed ID: 26307164 [TBL] [Abstract][Full Text] [Related]
65. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. Weisman LE; Fischer GW; Thackray HM; Johnson KE; Schuman RF; Mandy GT; Stratton BE; Adams KM; Kramer WG; Mond JJ Int Immunopharmacol; 2009 May; 9(5):639-44. PubMed ID: 19268719 [TBL] [Abstract][Full Text] [Related]
66. Inhibition of staphylococcal alpha-hemolysis by monoclonal antibodies against oligomer 12 S alpha-toxin. Amend A; Brückler J; Neubüser U; Blobel H Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Dec; 260(4):443-7. PubMed ID: 3834718 [TBL] [Abstract][Full Text] [Related]
67. Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage. Creech CB; Johnson BG; Alsentzer AR; Hohenboken M; Edwards KM; Talbot TR Vaccine; 2009 Dec; 28(1):256-60. PubMed ID: 19799842 [TBL] [Abstract][Full Text] [Related]
68. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. François B; Mercier E; Gonzalez C; Asehnoune K; Nseir S; Fiancette M; Desachy A; Plantefève G; Meziani F; de Lame PA; Laterre PF; Intensive Care Med; 2018 Nov; 44(11):1787-1796. PubMed ID: 30343314 [TBL] [Abstract][Full Text] [Related]
72. In Vivo Detection of González MI; González-Arjona M; Cussó L; Morcillo MÁ; Aguilera-Correa JJ; Esteban J; Kestler M; Calle D; Cerón C; Cortes-Canteli M; Muñoz P; Bouza E; Desco M; Salinas B Int J Biomed Imaging; 2024; 2024():3655327. PubMed ID: 38665417 [TBL] [Abstract][Full Text] [Related]
73. Recent advances in immunotherapies against infectious diseases. Ramamurthy D; Nundalall T; Cingo S; Mungra N; Karaan M; Naran K; Barth S Immunother Adv; 2021 Jan; 1(1):ltaa007. PubMed ID: 38626281 [TBL] [Abstract][Full Text] [Related]
74. Immunotherapies against human bacterial and fungal infectious diseases: A review. Qadri H; Shah AH; Alkhanani M; Almilaibary A; Mir MA Front Med (Lausanne); 2023; 10():1135541. PubMed ID: 37122338 [TBL] [Abstract][Full Text] [Related]
75. Molecular Assessment of Staphylococcus Aureus Strains in STAT3 Hyper-IgE Syndrome Patients. Schwierzeck V; Effner R; Abel F; Reiger M; Notheis G; Held J; Simon V; Dintner S; Hoffmann R; Hagl B; Huebner J; Mellmann A; Renner ED J Clin Immunol; 2022 Aug; 42(6):1301-1309. PubMed ID: 35655107 [TBL] [Abstract][Full Text] [Related]
76. Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin. Spaan AN; Neehus AL; Laplantine E; Staels F; Ogishi M; Seeleuthner Y; Rapaport F; Lacey KA; Van Nieuwenhove E; Chrabieh M; Hum D; Migaud M; Izmiryan A; Lorenzo L; Kochetkov T; Heesterbeek DAC; Bardoel BW; DuMont AL; Dobbs K; Chardonnet S; Heissel S; Baslan T; Zhang P; Yang R; Bogunovic D; Wunderink HF; Haas PA; Molina H; Van Buggenhout G; Lyonnet S; Notarangelo LD; Seppänen MRJ; Weil R; Seminario G; Gomez-Tello H; Wouters C; Mesdaghi M; Shahrooei M; Bossuyt X; Sag E; Topaloglu R; Ozen S; Leavis HL; van Eijk MMJ; Bezrodnik L; Blancas Galicia L; Hovnanian A; Nassif A; Bader-Meunier B; Neven B; Meyts I; Schrijvers R; Puel A; Bustamante J; Aksentijevich I; Kastner DL; Torres VJ; Humblet-Baron S; Liston A; Abel L; Boisson B; Casanova JL Science; 2022 Jun; 376(6599):eabm6380. PubMed ID: 35587511 [TBL] [Abstract][Full Text] [Related]
77. Human Monoclonal Antibodies to Escherichia coli Outer Membrane Protein A Porin Domain Cause Aggregation but Do Not Alter Fowler BD; Kose N; Reidy JX; Handal LS; Skaar EP; Crowe JE Infect Immun; 2022 Jun; 90(6):e0017622. PubMed ID: 35583347 [TBL] [Abstract][Full Text] [Related]
78. Development of Combination Vaccine Conferring Optimal Protection against Six Pore-Forming Toxins of Staphylococcus aureus. Zhang Q; Jiang T; Mao X; Kim JD; Ahn DH; Jung Y; Bae T; Lee BL Infect Immun; 2021 Sep; 89(10):e0034221. PubMed ID: 34227839 [TBL] [Abstract][Full Text] [Related]
79. Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci. Speziale P; Pietrocola G Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34064471 [TBL] [Abstract][Full Text] [Related]
80. Epidemiological and Clinical Evidence for the Role of Toxins in Bennett MR; Thomsen IP Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32575633 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]